184 related articles for article (PubMed ID: 29702708)
21. A Double-Blind, Randomized, Placebo-Controlled Trial of 17 Alpha-hydroxyprogesterone Caproate in the Management of Preterm Premature Rupture of Membranes.
Langen ES; Sit A; Sherwin K; Lyell DJ; Blumenfeld YJ; El-Sayed YY
Am J Perinatol; 2018 Jul; 35(8):779-784. PubMed ID: 29298456
[TBL] [Abstract][Full Text] [Related]
22. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
[TBL] [Abstract][Full Text] [Related]
23. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Caritis SN; Rouse DJ; Peaceman AM; Sciscione A; Momirova V; Spong CY; Iams JD; Wapner RJ; Varner M; Carpenter M; Lo J; Thorp J; Mercer BM; Sorokin Y; Harper M; Ramin S; Anderson G;
Obstet Gynecol; 2009 Feb; 113(2 Pt 1):285-92. PubMed ID: 19155896
[TBL] [Abstract][Full Text] [Related]
24. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
[TBL] [Abstract][Full Text] [Related]
25. Rationale for current and future progestin-based therapies to prevent preterm birth.
Weatherborn M; Mesiano S
Best Pract Res Clin Obstet Gynaecol; 2018 Oct; 52():114-125. PubMed ID: 29724668
[TBL] [Abstract][Full Text] [Related]
26. Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial.
Shaamash AH; Ali MK; Attyia KM
J Obstet Gynaecol; 2020 Jul; 40(5):633-638. PubMed ID: 31670998
[TBL] [Abstract][Full Text] [Related]
27. Re-examining the Meis Trial for Evidence of False-Positive Results.
Sibai B; Saade GR; Das AF
Obstet Gynecol; 2020 Sep; 136(3):622-627. PubMed ID: 32769653
[TBL] [Abstract][Full Text] [Related]
28. Defining the clinical response to 17-alpha hydroxyprogesterone caproate.
Caritis SN; Hauspurg A; Venkataramanan R; Lemon L
Am J Obstet Gynecol; 2018 Dec; 219(6):623-625. PubMed ID: 30171841
[No Abstract] [Full Text] [Related]
29. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
Hines M; Lyseng-Williamson KA; Deeks ED
Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
[TBL] [Abstract][Full Text] [Related]
30. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.
Grobman WA; Thom EA; Spong CY; Iams JD; Saade GR; Mercer BM; Tita AT; Rouse DJ; Sorokin Y; Wapner RJ; Leveno KJ; Blackwell S; Esplin MS; Tolosa JE; Thorp JM; Caritis SN; Van Dorsten JP;
Am J Obstet Gynecol; 2012 Nov; 207(5):390.e1-8. PubMed ID: 23010094
[TBL] [Abstract][Full Text] [Related]
31. Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate.
Szychowski JM; Berghella V; Owen J; Hankins G; Iams JD; Sheffield JS; Perez-Delboy A; Wing DA; Guzman ER;
J Matern Fetal Neonatal Med; 2012 Dec; 25(12):2686-9. PubMed ID: 22889234
[TBL] [Abstract][Full Text] [Related]
32. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
[TBL] [Abstract][Full Text] [Related]
33. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
Fukuda T; Kyozuka H; Murata T; Yasuda S; Yamaguchi A; Fujimori K
J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
[TBL] [Abstract][Full Text] [Related]
34. Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.
Fried I; Beam AL; Kohane IS; Palmer NP
JAMA Intern Med; 2017 Nov; 177(11):1689-1690. PubMed ID: 28973537
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
Wood SL; Williams BN; Szychowski JM; Owen J
Am J Perinatol; 2020 Jun; 37(7):659-665. PubMed ID: 31756763
[TBL] [Abstract][Full Text] [Related]
36. Next generation strategies for preventing preterm birth.
Zierden HC; Shapiro RL; DeLong K; Carter DM; Ensign LM
Adv Drug Deliv Rev; 2021 Jul; 174():190-209. PubMed ID: 33895215
[TBL] [Abstract][Full Text] [Related]
37. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
[TBL] [Abstract][Full Text] [Related]
38. Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation.
Megli C; Combs CA; Venkataramanan R; Lemon L; Caritis SN
Am J Perinatol; 2022 Aug; 39(11):1183-1188. PubMed ID: 33321529
[TBL] [Abstract][Full Text] [Related]
39. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Caritis SN; Costantine MM; Clark S; Stika CS; Kiley JW; Metz TD; Chauhan SP; Venkataramanan R;
Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of progesterone for prevention of preterm birth.
Sykes L; Bennett PR
Best Pract Res Clin Obstet Gynaecol; 2018 Oct; 52():126-136. PubMed ID: 30266582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
